Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
An announcement from Protara Therapeutics ( (TARA) ) is now available.
Protara Therapeutics has announced the closing of a public offering of common stock and pre-funded warrants, raising approximately $100 million in gross proceeds. The funds are intended for the development of TARA-002 and other clinical programs, with potential additional use for working capital and corporate purposes, highlighting Protara’s commitment to advancing its therapeutic pipeline.
More about Protara Therapeutics
Protara Therapeutics, Inc. is a clinical-stage company focused on developing transformative therapies for cancer and rare diseases.
YTD Price Performance: 232.45%
Average Trading Volume: 2,138,584
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $128.9M
See more insights into TARA stock on TipRanks’ Stock Analysis page.
Trending Articles
- Target (NYSE:TGT) Has a New Santa, Backed By AI
- The New Ford (NYSE:F) Translator May Be Coming Soon
- Intel (NASDAQ:INTC) Is Considering Breaking Off Its Manufacturing Lineup
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
